CA
NZ
UK
AU
IND
US
The transaction also ties the potential addition of G3’s estimated $111 million of 2025 net revenues to Profusa’sBalance Sheet, offering investors a clear pathway to expanded diagnostic services.
New Medicaid work requirements set to roll out could leave many patients vulnerable to losing their coverage, prompting serious concerns from advocates for rare diseases. These requirements may complicate access to important healthcare for individuals already facing significant health challenges. As patients grapple with …
The fiscal year 2028 sales target for Schaeffler AG has been reduced significantly from a prior range of €27 billion to €29 billion down to between €24 billion and €26 billion. This 10% decrease reflects the company's response to declining market expectations, particularly in …
Silexion Therapeutics Corp is undergoing a leadership transition after Professor Amnon Peled announced his resignation from the board of directors, effective August 1, 2026. The departure arises due to personal reasons and is not linked to any disagreements over the company's operations. This change …
Stryker Corp (NYSE: SYK) announced earnings per share (EPS) of $3.30 for the second quarter of 2026, underperforming against a consensus estimate of $3.01. The company also reported net sales of $6.6 billion, reflecting a significant 9.4% growth year-over-year. Although the EPS represents an …
Swedish Orphan Biovitrum AB (publ) (OTC: BIOVF) shares declined 1.7% to $48.20 in recent trading following news that its chief executive officer is departing the company. The immediate market reaction suggests investor apprehension regarding a leadership transition at the $162.3 billion pharmaceutical firm. This …
Tenax Therapeutics, Inc. (Nasdaq: TENX) reported an EPS loss of $-0.35 for the quarter ended June 30, 2026, better than the consensus estimate of $-0.41. This quarter marks a significant moment for Tenax, as the firm prepares for the upcoming topline data from its …
The weight-loss market is experiencing a significant shift as Americans increasingly go direct with GLP-1 prescriptions, benefiting retail pharmacy chains such as Walmart, Costco, and Amazon. This trend is driven by the growingDemandfor weight-loss solutions, with GLP-1 being a popular choice. As a result, …
Precipio (Nasdaq: PRPO) posted earnings per share of $0.05 for the quarter ended June 30, 2025 and confirmed a shareholder update call slated for Aug 17, 2026 at 5 p.m. ET. Investors will gauge whether the modest EPS figure translates into broader momentum for …
This announcement signifies a key moment for shareholders, who can now confidently anticipate receiving additional shares once specific price milestones are met, without a subsequent dilution from stock price adjustments. The clear communication from Nasdaq is set to influence investor behavior positively, as it …
Please wait processing your request...